biostudies-literatureUnknown11(2)Planchard D<h4>Background</h4>The first-line (1L) standard of care for B-Raf proto-oncogene (BRAF)^V600E-mutant metastatic non-small cell lung cancer is BRAF inhibitor dabrafenib with MEK inhibitor trametinib (D + T). Combination therapy with encorafenib and binimetinib (E + B) has recently demonstrated clinical benefit in this setting in the single-arm, phase II PHAROS trial. We evaluated the relative efficacy and safety of E + B versus D + T in 1L using an unanchored matching-adjusted indirect comparison.<h4>Material and methods</h4>Individual patient data for E + B from PHAROS were matched on validated adjustment factors to aggregate data for D + T from Study BRF113928. The relative efficacy and safety of E + B versus D + T were assessed using weighted Cox proportional hazards models forESMO open106051https://www.ebi.ac.uk/biostudies/studies/S-EPMC12865620biostudies-literatureEncorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF&lt;sup&gt;V600E&lt;/sup&gt;-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.PMC12865620Le Reun CMacabeo BGrouin JMPlanchard DMazieres JBoussahoua MLuttenauer HfalseEncorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF&lt;sup&gt;V600E&lt;/sup&gt;-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.<h4>Background</h4>The first-line (1L) standard of care for B-Raf proto-oncogene (BRAF)^V600E-mutant metastatic non-small cell lung cancer is BRAF inhibitor dabrafenib with MEK inhibitor trametinib (D + T). Combination therapy with encorafenib and binimetinib (E + B) has recently demonstrated clinical benefit in this setting in the single-arm, phase II PHAROS trial. We evaluated the relative efficacy and safety of E + B versus D + T in 1L using an unanchored matching-adjusted indirect comparison.<h4>Material and methods</h4>Individual patient data for E + B from PHAROS were matched on validated adjustment factors to aggregate data for D + T from Study BRF113928. The relative efficacy and safety of E + B versus D + T were assessed using weighted Cox proportional hazards models for2026-01-01T00:00:00Z2026 Jan2026-07-15T12:07:28.817Z2026-07-04T03:12:38.608ZS-EPMC128656204160482010.1016/j.esmoop.2025.106051